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Abstract: Diabetes mellitus is a common endocrine disease in cats. While type 2 diabetes is the 
most common form seen in cats, other underlying causes may contribute to insulin resistance. 
Guidelines for diagnosis vary and often do not take into account prediabetic cats. The goals of 
treatment are to maximize the chance of remission, while minimizing the risks of hypoglycemia. 
This article presents a further overview of current treatment and monitoring recommendations 
for diabetic cats.
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Diabetes in cats
The reported prevalence of feline diabetes mellitus (diabetes) varies from 1 in 100 (1%) 
to 1 in 400 (0.25%) depending on the population studied.1–5 An American study has 
reported the prevalence increasing over the past 30 years, from 1 in 1250 (0.08%) in 
1970 to 1 in 81 (1.2%) in 1999, though the contribution of increased diagnosis versus 
increased prevalence is unclear.5 Increased susceptibility has been reported in Burmese 
in Australia, New Zealand, and Europe, and Maine Coon, Russian Blue, and Siamese 
were reported in the USA and Norwegian Forest cats in Europe.3,4,6–8 Burmese cats in 
Australia and the UK are four times more likely to develop diabetes, with 1 in 10 cats 
aged ≥8 years affected.2–4
Diabetes is caused by insufficient insulin secretion from pancreatic β cells result-
ing in persistent hyperglycemia. Current classification in veterinary medicine is based 
on human diabetes and the mechanism involved in pancreatic β-cell failure. There 
are four types of diabetes: type 1, type 2, gestational, and other specific types.9 Type 
1 diabetes is characterized by immune-mediated destruction of β cells leading to an 
absolute insulin deficiency and it is extremely rare in cats.10,11 Gestational has not been 
reported in cats but reported in dogs.12
Type 2 diabetes is the most common form seen in cats, accounting for ~90% of 
cases.13,14 It is characterized by insulin resistance accompanied by failure of β cells to 
compensate in response to maintain euglycemia.9 Risk factors include increased age, 
male gender, obesity, indoor confinement, physical inactivity, breed, and long-acting 
or repeated steroid or megestrol acetate administration.1,4,5,15 These factors lead to 
decreased insulin sensitivity, and increase the demand on β-cells to produce insulin.16–18
The key features of type 2 diabetes are reduced insulin sensitivity (insulin resis-
tance) and reduced insulin secretion secondary to β-cell failure. Cats with diabetes are 
approximately six times less sensitive to insulin than normal cats.16,19 β Cells in healthy 
cats are able to respond to changing insulin requirements and produce more insulin 
when the demand is increased.20 Factors associated with type 2 diabetes impair the 
ability to secrete insulin.21 Mechanisms that impair β cells result in reduced  capacity 
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to proliferate to meet the increased demand for insulin, 
impair insulin secretion, decrease insulin gene expression, 
and eventually lead to uncontrolled β-cell death.21 Chronic 
hyperglycemia creates a continuous cycle of progressive loss 
of insulin secretion.22–24
Other specific types of diabetes include all other causes 
of diabetes. In cats, this can be caused by loss of pancreatic 
islets from pancreatitis or neoplasia (adenocarcinoma is 
reported in 8%–19% of euthanased diabetics in US tertiary 
referral institutions).10,25 Pancreatitis may be present in up 
to 60% of diabetic cats based on biochemical and imaging 
findings.26–28 In the majority of these cases, pancreatitis alone 
does not seem to be sufficiently severe to cause diabetes, 
but it does contribute to β-cell loss and may influence the 
probability of diabetic remission.28,29 Other specific types 
also include marked insulin resistance secondary to hyperso-
matotrophism (acromegaly) or hyperadrenocorticism (Cush-
ing syndrome).10,25,30,31 Acromegaly is the most commonly 
reported form, typically presenting as poorly controlled 
diabetes, despite the use of insulin doses that would normally 
be considered adequate.32
Diagnosis
The classical clinical signs of diabetes in cats are polyuria, 
polydipsia, and weight loss. Glycosuria occurs when blood 
glucose concentration exceeds the capacity of the proximal 
tubule to reabsorb glucose from the glomerular filtrate (~14–
16 mmol/L [250–290 mg/dL]), and the resulting osmotic 
dieresis leads to polyuria and compensatory polydipsia.33,34
Screening and fasting blood glucose 
concentrations
Diagnosis is made based on blood glucose concentration; 
however, currently, there is no commonly accepted lower 
cut point for diabetes in cats, with values of ≥180–288 mg/
dL (10–16 mmol/L) reported as diagnostic.35,36
Fasted blood glucose concentration in cats is ~3.0–6.5 
mmol/L (117 mg/dL) when measured using a portable glu-
cose meter calibrated for feline blood after overnight hospital-
ization and withholding food for 18–24 hours.37,38 Screening 
blood glucose (measured on entry to the consult room) has an 
upper reported cut point of 166 mg/dL (9.2 mmol/L), showing 
the potential effect of stress on diagnosis of diabetes in cats.39 
Acute stress can markedly increase glucose concentrations 
within 5 minutes and may last for 3 hours or longer.40 Strug-
gling can increase glucose concentration on average by 74 
mg/dL (4.1 mmol/L) and up to 195 mg/dL (10.8 mmol/L) 
within 10 minutes, associated with increased lactate and 
norepinephrine concentrations.40 Cats ≥8 years of age with 
a screening blood glucose >117 mg/dL (6.5 mmol/L) should 
be admitted and retested 4 hours later, and if not <117 mg/dL 
(6.5 mmol/L) then should be retested after 24 hours. While 
there are no longitudinal studies looking at nondiabetic cats 
with increased blood glucose concentrations, cats in diabetic 
remission with mildly increased blood glucose concentration 
(>135 to <162 mg/dL; 7.5 to <9 mmol/L) are at increased 
risk of becoming diabetic within 9 months.38 Therefore, 
identification of possible prediabetes and subclinical diabetes 
and appropriate intervention are likely useful for delaying or 
preventing progression to clinical diabetes in cats.
Hyperglycemia and the sick cat
In hospitalized sick cats, it can be unclear whether stress or 
diabetes is causing an elevated blood glucose concentration. 
If hyperglycemia (216 mg/dL; >12 mmol/L) persists for 
longer than 4–6 hours, low-dose insulin therapy (e.g., 0.5–1 
U/cat or 0.2 U/kg q 12 hours) should be given. Exogenous 
insulin lowers blood glucose and helps overcome deleteri-
ous effects of hyperglycemia on β-cell function. Glucose 
concentrations should be monitored closely and insulin 
adjusted accordingly.
Fructosamine
Fructosamine is produced by a nonenzymatic reaction 
between glucose and the amino groups of plasma proteins. 
It is useful to measure glycemic control for cats where home 
or in-hospital blood glucose monitoring is not possible, 
though its usefulness to aid diagnosis of diabetes is vari-
able. In cats, fructosamine concentration probably reflects 
the mean blood glucose concentration for the preceding 
week, and only changes >33 μmol/L in an individual cat 
have significance.41 Fructosamine concentrations can vary 
widely between individual cats for a given blood glucose 
concentration. While sensitivity and specificity of fructos-
amine for differentiating diabetic from nondiabetic cats 
have been demonstrated at 93% and 86%, respectively, 
false-positive results (normal cats with high fructosamine 
levels) and false-negative results (diabetic cats with normal 
fructosamine levels) do occur.42,43 Fructosamine should not 
be relied upon to differentiate stress–hyperglycemia from 
diabetes when the blood glucose concentration is ≤360 mg/
dL (20 mmol/L), because persistent hyperglycemia of this 
magnitude often does not increase fructosamine above the 
reference range.41 Differentiation should be based on serial 
blood glucose concentrations, and if present, glycosuria and 
consistent clinical signs.
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Treatment and monitoring
The aim of therapy in newly diagnosed diabetic cats is to 
maximize the chance of remission by strict glycemic control 
(72 to <180 mg/dL; 4 to <10 mmol/L), while avoiding hypo-
glycemia. Diabetic remission is defined as persistent eugly-
cemia without the requirement for exogenous insulin or oral 
hypoglycemic therapy in cats previously requiring treatment 
to control diabetic signs.13,38,44 For long-term diabetic cats that 
do not achieve remission (≥6 months), the aim is to control 
clinical signs and avoid clinical hypoglycemia. Remission 
may occur in a small proportion even after 2 years of insulin 
treatment, if rigorous glycemic control is maintained.
In newly diabetic cats, early effective glycemic control 
can resolve glucotoxicity before there is permanent loss of 
sufficient β cells to maintain euglycemia, which increases the 
probability of remission. A protocol aimed at strict glycemic 
control within 6 months of diagnosis showed that 84% of cats 
achieved diabetic remission compared with 35% (p<0.001) 
when strict glycemic control was not instituted for ≥6 months 
after diagnosis.45
Besides early institution of tight glycemic control, factors 
associated with remission include a low-carbohydrate diet 
(12% versus 26% of energy from carbohydrate), long-acting 
insulin (glargine versus PZI or lente), higher age (suggesting 
possible slower disease progression), lower maximum dose of 
insulin (mean maximum dose of glargine of 0.4 U/kg versus 
0.7 U/kg or <3 U/cat versus >3 U/cat), lower mean blood 
glucose after treatment with insulin, and lower cholesterol 
concentrations.13,44–47 Corticosteroid administration in the 6 
months before diagnosis of diabetes is associated with sig-
nificantly higher remission rates.45 Peripheral neuropathy at 
diagnosis is associated with decreased probability of remis-
sion. This is likely because diabetic neuropathy presents later 
in the course of disease, so these cats have been diabetic for 
longer period of time and have greater β-cell damage.45
To maximize the probability of remission, blood glucose 
concentration is the most useful guide for adjustment of 
insulin dose. Home blood glucose monitoring is recom-
mended to avoid the effects of stress hyperglycemia, and 
it should be measured prior to insulin injection, to prevent 
inadvertent overdosing of insulin when blood glucose con-
centration is around the normal range. Ideally, normal or 
near-normal blood glucose concentrations (54–180 mg/dL; 
3–10 mmol/L) will be achieved over each 24-hour period, 
and clinical signs will resolve. Clinical signs themselves are 
relatively insensitive indicators of glycemic control when 
glucose concentration is below the renal threshold (252–288 
mg/dL; 14–16 mmol/L).
Continuous blood glucose monitoring
Blood glucose concentration is best measured either with 
a portable glucose meter calibrated for feline blood, and 
measured from the ear or paw pad, or with a continuous 
glucose meter which is internally calibrated and has a long 
sensor life. Continuous blood glucose monitors measure 
glucose concentration in the interstitial fluid, mostly using 
an electrochemical sensor attached to a small monitor or 
transmitter implanted subcutaneously in the flank, lateral 
thorax, interscapular space, or dorsal neck in cats.48 The Min-
iMed Gold (Medtronic), Guardian Real-Time (Medtronic), 
GlucoDay (Menarini Diagnostics), iPro (Medtronic), and 
FreeStyle Libre (Abbott) have been reported for use in cats 
and dogs.48,49 However, many models still require calibration 
three times a day with blood glucose measurements obtained 
by traditional methods, most sensors need replacing every 
3–7 days, and the glucose recording range can be limited. The 
FreeStyle Libre (Abbott) is a newer model that is calibrated 
in the factory and does not require additional blood glucose 
measurements to calibrate at home, and the sensor is suitable 
for 14 days of use.50
Continuous glucose monitors are useful for hospitalized 
patients needing intensive monitoring; however, they are 
also useful for home use for diabetic cats that are difficult 
to stabilize as they allow identification of short duration of 
insulin action and Somogyi events. Guardian Real-Time is 
useful for hospitalized cats requiring real-time displays for 
monitoring.48 For home monitoring, the FreeStyle Libre has 
several benefits as listed above making it the most suitable 
choice, though there are some limitations.49
Insulin therapy
The most effective treatment for achieving excellent glycemic 
control is insulin, with several types available for use in cats.13
Lente insulin (Caninsulin/Vetsulin)
Lente insulin is an intermediate-acting insulin.51 Caninsulin 
or Vetsulin (Merck Animal Health) is a porcine-derived 
lente insulin licensed for use in cats in many countries. The 
concentration of 40 U/mL differs from insulin registered for 
human use and some veterinary-registered insulins, which 
are 100 U/mL. It is important that the appropriate 40 U/
mL syringes are not inadvertently changed for 100 U/mL 
syringes.
Starting dose for lente insulin is 0.25–0.5 IU/kg body 
weight, q 12 hours, and should not exceed 3 IU/cat.52 In a 
12-month study of 25 cats (15 newly diagnosed), 84% were 
considered to have a good or excellent response to treatment, 
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based on owner satisfaction and resolution of clinical signs, 
and 28% achieved diabetic remission within 16 weeks of 
starting treatment.53 Another study of 46 cats (39 newly diag-
nosed) showed that good to excellent control was achieved 
in 72%, based on the resolution of clinical signs, and 15% 
achieved remission within 20 weeks.54
In diabetic cats, nadir blood glucose concentration 
typically occurs 3–6 hours (mean 4 hours) after insulin 
administration, and blood glucose concentration returns to 
preinjection concentrations ranging from 8 to 10 hours after 
insulin administration (termed return to baseline or duration 
of action).54,55 Because of this relatively short duration of 
lente action, even with twice-daily dosing, hyperglycemia 
typically occurs for 2–3 hours twice daily prior to each injec-
tion, which likely contributes to lower remission rates in cats 
treated with this insulin.55,56
Protamine zinc insulin
Protamine zinc insulin (PZI; ProZinc, Boehringer Ingelheim) 
is available for use in cats in the US and UK, having been 
removed from the human market in the 1990s. ProZinc has 
a concentration of 40 U/mL, and therefore, use of appropri-
ate insulin syringes must be discussed as with lente insulin. 
While ProZinc is a human recombinant insulin, some com-
pounding pharmacies in the US still provide bovine-origin 
PZI for veterinary use; however, studies have shown incon-
sistencies in compounded products.57
Initial doses recommended are either 1–3 U/cat (0.22–
0.66 units/kg) or 0.25–0.5 units/kg ideal body weight, 
depending on the severity of clinical signs and hyperglyce-
mia.13,58 Of the 133 diabetic cats treated with PZI (120 newly 
diagnosed and 13 previously treated with other insulin), 85% 
obtained good control within 45 days.58 In a comparative 
study of 24 newly diagnosed diabetics, 38% (3/8) of 8 cats 
treated with PZI achieved remission within 112 days, which 
was not significantly different to remission rates achieved in 
25% (2/8) of cats treated with lente insulin.13
Glargine
Glargine (Lantus; 100 U/mL) is a long-acting human insulin 
analog that is soluble in acidic solutions but forms micropre-
cipitates in the neutral pH of the subcutaneous tissue. These 
microprecipitates slowly release small amounts of insulin 
over 24 hours.59,60 In healthy cats, the duration of action is 
significantly longer than lente insulin (10 hours, range 5 to 
>24), though similar to PZI (21 hours, range 9 to >24).61
Glargine is used together with a low-carbohydrate diet 
to minimize prandial increases in blood glucose in cats. 
 Twice-a-day administration is recommended to provide over-
lap of insulin action from the proceeding injection and increase 
the probability of remission.61–63 The starting dose for glargine 
is 0.25 U/kg of ideal body weight, if blood glucose concen-
tration is <360 mg/dL (<20 mmol/L) or 0.5 U/kg if blood 
glucose is >360 mg/dL.13,64 When transitioning to glargine 
from another insulin, for doses <3 IU direct substitution is 
usually suitable; however, for doses >3 IU, conservative dosing 
of half to two-thirds of the dose is recommended, but it will 
be increased within 48–72 hours if control is not adequate.65
Significantly higher remission rates were achieved by 
16 weeks of treatment with glargine (8/8 cats), compared 
with lente insulin (2/8) and PZI (3/8) in newly diagnosed 
diabetics fed a low-carbohydrate diet (6% of energy from 
carbohydrate).13 In 55 diabetic cats, the remission rate was 
84% when glargine was started within 6 months of diagnosis 
using protocol aimed at achieving euglycemia.45 However, 
a recent clinical trial of 46 cats found that while a higher 
percentage of cats receiving glargine went into remission 
compared with those treated with PZI (33.3%versus 23%), 
this was not significantly different.66
Detemir
Detemir (Levemir, NovoNordisk) is a long-acting human insu-
lin analog (100 μ/mL). While once-a-day dosing is adequate 
for humans, the duration of action in healthy cats is shorter and 
twice-daily dosing is recommended.62 Initial doses for detemir 
are similar to glargine, with 0.5 units/kg if blood glucose con-
centration is >360 mg/dL (20 mmol/L) and 0.25 units/kg if 
<360 mg/dL.64 Cats may require ~25%–30% lower maximum 
dose of detemir than glargine initially.45 Cats can exhibit an 
initial increased sensitivity to detemir for 24–48 hours; thus, if 
changing from glargine or other insulin, start with about half the 
dose of glargine and increase dose within 48 hours if insufficient 
glucose lowering occurs. Home monitoring is recommended 
because preinsulin blood glucose concentrations vary daily. 
Increase dose based on the same dosing protocol as glargine.64,65
Of the 11 cats treated with detemir within 6 months of 
diagnosis and a protocol aimed at euglycemia, 81% went into 
remission, whereas only 42% of 6 cats that had been diabetic 
for longer than 6 months achieved remission, findings similar 
to glargine-treated cats.67
Degludec
Degludec (Tresiba, NovoNordisk) is an ultralong-acting 
insulin with a longer half-life. Due to its slow release, there 
is no peak in activity, and it is less likely to result in hypo-
glycemia.68 Its use has not been reported in cats.
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Choosing an insulin
Given the high rates of diabetic remission in recent stud-
ies using long-acting insulin, low-carbohydrate diets, and 
protocols aimed at achieving normal or near-normal blood 
glucose concentrations, insulin should be chosen to maximize 
the probability of diabetic remission. Glargine and detemir 
are the only insulins reportedly associated with remission 
rates of >80% in newly diagnosed cats when combined with 
a low-carbohydrate diet, and hence, these should be the first 
choice when choosing insulin for a newly diagnosed diabetic 
cat.13,67 However, neither is registered for use in cats, and 
in some countries (e.g., the UK), laws may require the use 
of a veterinary-approved product first. Because the highest 
remission rates occur in cats that are managed with a protocol 
aimed at achieving euglycemia within 6 months of diagnosis, 
the requirement to treat with another insulin first may reduce 
the probability of remission.
Diet
Cats are obligate carnivores, with diets of feral cats eating 
natural prey having a mean daily energy intake of ~2% car-
bohydrate (nitrogen-free extract), 52% crude protein, and 
46% crude fat.69 However, commercial feline dry food diets 
have up to 60% of their energy from carbohydrates (mean 
41%).5,70,71 Compared with dogs and humans, cats have a 
reduced capacity to metabolize a high glucose load, resulting 
in higher blood glucose concentrations after a carbohydrate 
load, and have an extended postprandial period of 8–15 hours 
compared with 2–3 hours for humans and 3–6 hours for 
dogs.9,72,73 While cats do exhibit some metabolic flexibility 
in dealing with dietary carbohydrates provided minimum 
protein requirements are met, glucose metabolism in cats is 
unique, resulting in a relative carbohydrate intolerance, as 
the gluconeogenic pathway is almost always permanently 
“switched on”.74,75 Delayed gastric emptying, reduced small 
intestinal disaccharidase activity, and reduced and delayed 
insulin secretion likely contribute to longer postprandial 
increase in blood glucose concentrations following a high 
carbohydrate load.73,76,77
Obesity is the most important acquired risk factor for 
diabetes, as overweight cats have 4.6 times greater risk of 
diabetes than cats in ideal body condition.4,16,35 Approximately 
20% of obese cats >8 years of age are prediabetic with 
impaired glucose tolerance or impaired fasting glucose.37,78,79
Low-carbohydrate diets (≤12% metabolizable energy 
[ME]) are indicated for cats at increased risk of diabetes, 
such as senior age, susceptible breed, and concurrent medica-
tions. Older cats with other risk factors for diabetes such as 
European or Australian Burmese and cats receiving repeated 
corticosteroid injections would likely benefit from a low-
carbohydrate diet to minimize the insulin secretion required 
to maintain euglycemia.80
The highest remission rates in diabetic cats (>80%) are 
reported using a very low-carbohydrate diet (<6% ME) in 
combination with protocols aimed at achieving normal or 
near-normal blood glucose concentrations.13,67 However, the 
relative contribution of diet in increasing the probability of 
remission is unknown.
Controlled weight loss via energy restriction is important 
to normalize the body condition and muscle mass in obese 
diabetic cats.80 A suitable weight loss diet for a diabetic cat is 
fat <4 g/100 kcal, carbohydrates <3 g/100 kcal, and protein 
>10 g/kcal.80 Increasing the proportion of wet food helps to 
decrease energy intake and body weight as moisture increases 
food volume and hydration.81 While not many cats achieve 
remission before reaching ideal body condition, maintain-
ing ideal body condition is likely important for maintaining 
remission.
Oral hypoglycemics
Oral hypoglycemics may be used in human type 2 diabetes 
patients with sufficient endogenous insulin secretion to 
maintain euglycemia without insulin therapy. Sulfonylureas 
and meglitinides stimulate insulin secretion from pancre-
atic β cells.82,83 However, the majority of diabetic cats have 
insufficient β-cell function to achieve good glycemic control 
using these alone.30,84 Similarly, biguanides such as met-
formin require functional β cells and sufficient circulating 
insulin to be present if they are the sole therapy.85 In five 
newly diagnosed diabetic cats treated solely with metfor-
min, only one cat had measurable serum insulin concentra-
tion pretreatment, and this was the only cat that achieved 
good glycemic control.86 While α-glucosidase inhibitors 
such as acarbose can slow intestinal glucose absorption 
and reduce peak postprandial glucose concentrations, 
they are minimally effective in cats eating multiple small 
meals.85,87 The trace element vanadium supplemented at 45 
mg/cat/day improved glycemic control in diabetics treated 
with PZI insulin, with a mean insulin requirement of 3 U 
in vanadium-supplemented cats compared with 5 U in cats 
treated with PZI alone.88
Insulin treatment is associated with a higher probability 
of achieving glycemic control and eventual diabetic remis-
sion, compared to the sole use of oral hypoglycemic agents, 
and this continues to be the recommended treatment for 
diabetic cats.
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New and emerging therapies
Incretins are gastrointestinal hormones released in response 
to food intake that stimulate the release of insulin and include 
glucagon-like peptide 1 (GLP-1) agonists and dipeptidylpepti-
dase-4 inhibitors.89 In humans with type 2 diabetes, exenatide 
(twice daily) and extended-release extenatide (once weekly) 
are injectable GLP-1 agonist preparations used as an adjunc-
tive or sole therapy. In newly diagnosed diabetic cats treated 
with glargine and a low-carbohydrate diet, 15 cats also treated 
with extended-release exenatide had improved glycemic con-
trol and remission rates compared with 15 cats that received a 
placebo, though this was not significant.90 Further studies are 
required to investigate their cost-effectiveness in diabetic cats.
Diabetic remission
Diabetic remission is the ideal outcome of treatment. How-
ever, ~25%–30% of diabetic cats in remission will relapse 
and require insulin treatment to be recommenced.38,44,46 The 
majority of cats that relapse do not achieve a second remission, 
although in one study of nine cats that relapsed, two achieved 
a second remission.45 Most diabetic cats in remission do not 
have normal β-cell function or sufficient insulin secretion to 
maintain normal glucose tolerance when challenged with an 
intravenous (IV) glucose tolerance test (GTT) and should be 
considered prediabetic. Approximately 76% have impaired 
glucose tolerance evident after a glucose challenge and 19% 
have impaired fasting glucose concentrations (mild persistent 
hyperglycemia >117 to <180 mg/dL; >6.5 to <10 mmol/L).38 
Monitoring with GTTs can identify cats at risk of relapsing. 
Fasting blood glucose of ≥135 mg/dL (≥7.5 mmol/L), severely 
impaired glucose tolerance (≥5 hours return to ≤117 mg/dL or 
≤6.5 mmol/L after a 1 g/kg glucose IV), and a blood glucose 
concentration during a GTT of >252 mg/dL (>14 mmol/L) at 
3 hours were all significantly associated with a relapse within 
9 months of achieving remission.38
Home blood glucose monitoring and GTTs should be 
used to detect those cats at greater risk of relapsing. Cats 
with persistent blood glucose concentrations >117 mg/dL 
(6.5 mmol/L) require management with low-carbohydrate 
diets and weight loss, if appropriate.91 Oral hypoglycemics, 
incretin-based therapies, or low-dose insulin therapy may 
have a role in managing cats with impaired glucose toler-
ance or fasting blood glucose to reduce the risk of relapse; 
however, further investigation is required.
Poorly controlled diabetic cats
Some diabetic cats will prove difficult to control, often requir-
ing high doses of insulin administration. This may be due to 
owner noncompliance, insulin choice, inappropriate dosing, 
or underlying diseases contributing to insulin resistance.
Inappropriate storage of insulin leading to loss of potency, 
incorrect administration (e.g., poor injection technique and 
drawing up air bubbles), and irregular dosing can all contrib-
ute to poorly controlled diabetes and should be ruled out as 
much as possible by discussing with the client and watching 
their injection technique. Dosing errors occur when one type 
of syringe is changed for another without proper education. 
Porcine lente insulin (40 U/mL, Vetsulin/Caninsulin, Intervet) 
and Prozinc use 40 U/mL syringes (1 gradation=0.025 mL), 
whereas other insulins use 0.3 mL, 100 U/mL syringes (1 
gradation=0.01mL). Duration of action of intermediate-acting 
insulins (e.g., lente) may not be sufficient with twice-daily 
dosing to maintain a prolonged decrease in blood glucose con-
centrations.55,61 In these cats, a change to longer acting insulin 
such as glargine or detemir typically resolves the poor control.
Underlying diseases can contribute to insulin resistance 
and poor control, despite good client compliance and appro-
priate insulin selection and dosing. Further testing should 
be offered if insulin doses exceed 1.0–1.5 IU/kg q 12 hours, 
and blood glucose control remains poor (mean blood glucose 
>270 mg/dL or 15 mmol/L).
Acromegaly, or hypersomatotropism, results from 
increased production of growth hormone, typically due to a 
pituitary adenoma, and accounts for 25%–30% or more of 
cases with poorly controlled diabetes. It is the most com-
mon underlying disease in cats with poor diabetic control.92 
Secretion of insulin-like growth factor-1 (IGF-1) is also 
increased, which mediates the anabolic changes associated 
with the disease, although many cats with acromegaly will 
have a normal appearance.32 Clinical signs include polyuria, 
polydipsia, polyphagia, and weight gain.
On average, acromegalic cats require insulin doses more 
than twice those required in nonacromegalic diabetics, though 
a small minority will initially have good glycemic control and 
may even achieve remission. Median insulin doses reported 
are 7 IU twice a day (range 1–35 IU), though sometimes 
extreme doses are required that would be fatal in other cats 
(20 to >70 IU).32,92
The most commonly used diagnostic test for acromegaly 
is IGF-1 testing, with concentrations typically increased 
>1000 mg/mL in acromegalic cats. It is recommended that 
IGF-1 testing be delayed until 6–8 weeks after insulin therapy 
is started, as insulinopenia present at the time of diabetic 
diagnosis may result in a falsely low concentration.32 Intracra-
nial imaging with magnetic resonance imaging or computed 
tomography is useful to confirm diagnosis.
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Treatment options include palliation with insulin, surgery, 
radiation, and medical management. Surgery and radiation 
are limited in their geographical availability, so palliation 
with high insulin doses accompanied by home blood glucose 
monitoring is the most common method used.
Hyperadrenocorticism is a less common cause of insulin 
resistance compared with acromegaly and rarely requires 
similarly high insulin doses.32 At diagnosis, ~80% of cats with 
hyperadrenocorticism are diabetic.93 Excessive endogenous 
glucocorticoid, associated with either a function tumor of 
the pituitary gland or the adrenal cortex, is associated with 
impaired insulin sensitivity and decreased insulin secretion 
from pancreatic β cells.32 Clinical signs include polyphagia, 
polyuria, polydipsia, weight loss, pot-bellied appearance, 
hepatomegaly, and skin fragility.94 A low-dose dexametha-
sone suppression test using 0.1 mg/kg dexamethasone IV is 
commonly used for diagnosis.
Pancreatitis is present at the time of diagnosis in 60% of 
diabetic cats based on biochemical and imaging findings, 
though few have clinical signs.10,28 Diabetic remission can 
be achieved in cats diagnosed with acute pancreatitis at the 
time of diagnosis of diabetes, and some may return to normal 
glucose tolerance with resolution of their disease.27 Home 
blood glucose monitoring and appropriate adjustment of 
insulin dose are recommended to maintain glycemic control 
and maximize the probability of remission.
Hyperthyroidism has been associated with impaired glu-
cose tolerance; however, it does not appear to cause clinically 
appreciable insulin resistance in most diabetic cats.95
Bacterial infection has been associated with decreased 
glucose tolerance, insulin resistance, and hyperinsulinemia 
in humans and dogs.96,97 Approximately 12%–13% of diabetic 
cats have urinary tract infections because of increased risk 
associated with glucosuria and decreased urine concentra-
tion.98,99 The most common urinary pathogen identified 
in diabetic cats is Escherichia coli.99 Fungal urinary tract 
infections, such as Candida albicans or Candida glabrata, 
have also been reported in cats.100,101 All cats with high insu-
lin requirements and poor control should have a thorough 
workup, including urine sediment exam, and appropriate 
treatment for any infections identified.
Renal disease
Diabetic nephropathy is diagnosed in 20%–40% of diabetic 
humans. Though not routinely recognized in diabetic cats, 
chronic kidney disease (CKD) (common in older cats) is 
reported in 26%–62% of diabetic cats.45,67,102 Tubulointer-
stitial nephritis is the most common histological finding in 
cats with renal disease; however, in a study of six diabetic 
cats, 50% had glomerular changes compatible with those 
seen in human diabetic nephropathy.103,104 Microalbuminemia 
and urine protein/creatinine ratio (using a 0.4 cutoff) have 
been demonstrated to be significantly higher in diabetic cats 
compared with healthy control cats.102,105
Controlled amounts of protein and restricted phosphorus 
improve the survival time in cats with chronic renal disease, 
and therefore, high-protein and low-carbohydrate diabetes 
diets recommended to manage diabetes are likely contrain-
dicated, especially in cats with IRIS stages 2 or 3 of CKD.106
Hypoglycemia
A potential complication of insulin treatment is hypoglyce-
mia, manifesting as either biochemical (or asymptomatic) 
hypoglycemia or clinical (symptomatic) hypoglycemia. 
Severe hypoglycemia (≤18 mg/dL or 1 mmol/L) is potentially 
life threatening as the brain requires a continual supply of 
glucose diffusing from the blood.107 Excessive insulin rapidly 
transports glucose into peripheral insulin-sensitive tissues, so 
insufficient glucose is left to adequately supply the brain.108
Clinical signs, if they occur (clinical hypoglycemia), 
include lethargy, depression, ataxia, seizures, or, in severe cases, 
coma. In cats, cutoffs for biochemical hypoglycemia in clinical 
insulin trials have been reported as <54 mg/dL or 3 mmol/L 
measured with a meter calibrated for whole human blood.13,45 
In 28 cats fasted and hospitalized overnight, the lower 95% 
CI for normal blood glucose concentration was 41 mg/dL (2.3 
mmol/L) measured with a meter calibrated for feline blood.38
Overadministration of insulin (iatrogenic hypoglycemia) 
may be caused by client error in drawing up the dose, or may 
follow an increase in the insulin dose or be associated with 
the recovery of endogenous insulin secretion.13 Insulin doses 
should be adjusted to meet the decreased insulin require-
ments in cats approaching diabetic remission; otherwise, 
hypoglycemia is likely. Overdose can occur when a 40 U/mL 
syringe (1 gradation =0.025 mL) is inadvertently substituted 
for a 0.3 mL, 100 U/mL syringe (1 gradation =0.01 mL) and 
can be life threatening.
Biochemical hypoglycemia is managed by feeding the 
cat, preferably a high-carbohydrate meal (>35% of energy 
from carbohydrate) and glucose containing solution (e.g., 
honey and glucose syrup) if mild clinical signs occur. Insulin 
administration should be stopped until hyperglycemia occurs 
(>117 mg/dL; 6.5 mmol/L or >216 mg/dL;12 mmol/L), then 
the dose should be reduced by 25%–50%.87,109
Severe clinical hypoglycemia (marked ataxia, seizures, 
and coma) is an emergency situation and requires hospital 
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admission. Prior to transport, owners can administer a con-
centrated glucose solution either orally or via the rectum 
using a Vaseline-lubricated syringe without a needle.107 Once 
hospitalized, treatment typically consists of an initial IV glu-
cose bolus (0.5 g/kg) and a continuous infusion of 2.5% until 
normal blood glucose concentration can be maintained.107,110
Rapid compensation for hypoglycemia in the body nor-
mally occurs by decreasing insulin production and stimulat-
ing glucagon from the pancreas and epinephrine from the 
adrenal medullae.111 However, glucagon’s production by 
pancreatic α cells in response to hypoglycemia is absent or 
diminished in diabetics.112 Glucagon injection kits are used to 
stimulate hepatic gluconeogenesis and glycolysis to increase 
blood glucose concentration in human diabetics with severe 
hypoglycemia.111 In hypoglycemic dogs, glucagon continu-
ous rate infusion (initial rate 5 ng/kg/min) was used for the 
treatment of refractory seizures in a dog with insulinoma and 
9 dogs with insulinoma, paraneoplastic hypoglycemia, and 
diabetic hypoglycemia (bolus and initial rate of 10–15 ng/
kg/min).113,114 Glucagon bolus markedly improved neurologic 
signs in a diabetic cat, which had persisted after euglycemia 
had been restored by dextrose infusion.113 No adverse effects 
were noted. Glucagon is initially given as a bolus of 50 ng/
kg and then administered at a rate of 10–15 ng/kg/min, but 
may need to be increased up to 40 ng/kg/min to maintain 
euglycemia.
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The authors report no conflicts of interest in this work.
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